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Objectives: The use of monoclonal anti-tumor necrosis factor (TNF) antibodies (infliximab, Remicade) is a new 
therapeutic approach for severe refractory luminal or fistulizing, Crohn's disease (CD). However, up to 30% of 
patients do not respond to this treatment. So far, no parameters predictive of response to anti-TNF have been 
identified. Our aim was to determine whether serological markers ASCA (anti-Saccharomyces cerevisiae 
antibodies) or pANCA (perinuclear antineutrophil cytoplasmic antibodies) could identify Crohn's patients likely 
to benefit from anti-TNF therapy. 
Methods: Serum samples of 279 CD patients were analyzed for ASCA and pANCA before anti-TNF therapy. A 
blinded physician determined clinical response at week 4 (refractory luminal CD) or week 10 (fistulizing CD) 
after the first infusion of infliximab (5 mg/kg). 
Results: Overall, there was no relationship between ASCA or pANCA and response to therapy. However, lower 
response rates were observed for patients with refractory intestinal disease carrying the pANCA+/ASCA- 
combination, although this lacked significance (p = 0.067). 
Conclusions: In this cohort of infliximab-treated patients, neither ASCA nor pANCA could predict response to 
treatment. However, the combination pANCA+/ASCA- might warrant further investigation for its value in 
predicting non-response in patients with refractory luminal disease. 
 
INTRODUCTION 
The inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC), are chronic intestinal 
disorders characterized by frequent flare-ups alternating with periods of remission. For many patients with active 
disease, corticosteroids, despite their side effects, are still the preferred first line therapy, although this treatment 
is not disease modifying. Recently, monoclonal chimeric antibodies (infliximab) to tumor necrosis factor (TNF), 
a drug with a more specific mechanism of action, have proved to be effective in both refractory and fistulizing 
CD. Approximately 70% of patients show response, with up to one third of patients entering clinical remission 
by 4 wk after a single-dose infusion (1). For fistulizing disease, 68% of patients showed a response and 55% had 
complete stop of drainage in the study by Present et al. (2). Infliximab is also the first drug that may induce 
important or complete mucosal healing in the short term (3, 4). 
However, for unknown reasons, the treatment fails in up to 30% of patients. Because of the severe problem of 
treatment refractoriness, factors that could predict response would be very helpful for designing treatment 
strategies in refractory IBD. So far, no reliable marker with sufficient predictive value for assessing treatment 
refractoriness could be identified. 
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Anti-Saccharomyces cerevisiae (ASCA) and perinuclear antineutrophil cytoplasmic antibodies (pANCA) are 
serological markers associated with CD and UC, respectively. ASCA are antibodies directed against 
oligomannosidic epitopes on the cell wall of S. cerevisiae. Approximately 60% of CD patients carry these 
antibodies (5-9). In addition, pANCA has been correlated with UC with a sensitivity of 60-80% (10-13). Of the 
CD patients, 5-10% also express pANCA. Mostly these patients present with left-sided colitis and respond well 
to topical therapy (14), although this has not been universally found (15). It was suggested that pANCA have 
predictive value with regard to the development of pouchitis after ileoanal pouch anastomosis for UC (16-18). 
Their presence in UC has also been associated with aggressive disease and early surgery (19). 
Because of their high specificity, ASCA and pANCA might be useful for differentiation between various 
phenotypes of IBD, but their low sensitivity makes the diagnostic value of these markers questionable. However, 
it has already been suggested that these antibodies might determine response to new therapeutic agents (20). 
Therefore, the aim of this study was to determine whether ASCA, pANCA, or a combination of both markers 
could define patient subgroups likely to benefit from anti-TNF treatment. 
MATERIALS AND METHODS 
Study Population 
A total of 279 patients with active Crohn's disease who were included in an expanded access program for 
treatment with infliximab (Schering-Plough NV, study P 01246-1) were studied. Of these, 89 patients received 
infusions for fistulizing Crohn's disease and 190 for refractory luminal CD. Demographic characteristics and 
baseline clinical information are given in Table 1. The diagnosis of Crohn's disease was based on internationally 
accepted criteria (21). 
The Crohn's Disease Activity Index (CDAI) (22) was calculated before infusion and at week 4 (refractory CD) or 
week 10 (fistulizing CD) after first infusion. Moreover, a physician blinded to the serological markers scored 
clinical response at week 4 or week 10. For refractory CD, a single infusion was given at week 0, according to 
the study protocol; response was considered complete if CDAI dropped to <150 or partial if CDAI decreased by 
>70 points (1). Patients with fisrulizing CD, who were treated with three consecutive infusions at week 0, 2, and 
6, were considered complete responders in case of complete stop of drainage from the fistulas and as partial 
responders when a decrease in 50% of the number of draining fistulas at two consecutive visits was seen (2). 
Both complete responders and partial responders were taken as responders. 
Whole venous blood was obtained at the first screening visit before inclusion in the trial and at week 4 
(refractory disease) or week 10 (fistulizing disease) after first infusion. Serum was separated after clotting by 
centrifugation and subsequently stored at -80°C until performance of the ASCA and pANCA assays. Serum C-
reactive protein (CRP) was measured before treatment at week 0 and at week 4 or week 10, respectively, after 
anti-TNF infusion. 
All patients gave informed consent and the Ethical Board of our institution approved the study. 
Table 1. Demographic and Baseline Clinical Characteristics of the Study Population 
Characteristic Total (n = 279) Fistulizing (n = 89) Refractory (n = 190) Significance (p) 
Female/male 177/102 61/28 116/74 ns 
Mean age [range] (yr) 36.2 [15-74] 38.2 [16-71] 35.3 [15-74] 0.041 
Mean age of initial diagnosis [range] (yr) 25.6 [7-71] 25.8 [8-61] 25.5 [7-71] ns 
Mean CDAI before treatment [range] 257 [11-609] 204 [17-480] 276 [11-609] <0.001 
Mean CRP before treatment [range] (mg/L) 27.8 [<3-163.4] 23.6 [<3-107.4] 29.3 [<3-163.4] ns 
Concomitant treatment     
Steroids 113 29 84  
5-ASA 122 44 78 ns 
Immunosuppressives (azathioprine, 6MP, 
MTX) 
151 52 99  
6MP = 6-mercaptopurine; MTX = methotrexate. 
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The ASCA was measured by a standardized ELISA using microtiterplates coated with phosphopeptidomannan 
(PPM), obtained through the Laboratoire de Parasitologie, Mycologie of the Center Hospitalier Universitaire 
(CHU) Lille, France (D. Poulain). A quantity of 100 µl of serum, diluted at 1/1000 in TNT, was added to each 
well, together with one positive and one negative control. Alkaline phosphatase-labeled goat antihuman IgG, 
IgA, IgM (heavy and fight chains) diluted at 1/1000 (100 µl) was used (Zymed Laboratories, San Fransisco, CA) 
as conjugate and substrate MAGIA (Merck Belgolabo, Overijse, Belgium) for alkaline phosphatase was added to 
obtain a color reaction. Plates were read at 405 nm on an automatic photometer (ANTHOS ht II). Absorbance of 
the individual sera was expressed relative to the absorbance of a pool of sera collected from well characterized 
CD patients. All determinations were done in double and the mean absorbance of both determinations was 
calculated. Previously, we showed that there is excellent reproducibility of measurements with this assay (r = 
0.993) (23). Based on receiver operating characteristic (ROC) curves, samples displaying an absorbance ≥3.12% 
were considered positive. 
pANCA Indirect Immunqfluorescence 
The pANCA was determined in the Laboratory of Immunology of the UZ Gasthuisberg (Leuven, Belgium) by 
indirect immunofluorescence (IIF) using ethanol-fixated neutrophil slides (Inova Diagnostics, San Diego, CA). 
Sera were incubated at a 1/40 dilution for 30 min at room temperature, washed and incubated with fluorescein 
isothiocyanate-labeled rabbit antihuman IgG immunoglobulin (Inova Diagnostics). Slides were then examined 
under UV using a Leitz Wetzler Orthoplan microscope (Germany). Sera that exhibited fluorescence on IIF were 
titred to endpoint. Interference by antinuclear antibodies, which may mimic the pANCA pattern, was ruled out 
by using formalin-fixed cells (Inova Diagnostic) as described by Wiik (1989) (24). Cut-off value for positivity 
was set at 1/40. 
Statistical Analysis 
Comparison of different groups was done using the χ2 test or Fisher's exact test when appropriate. The paired t 
test was used to analyze paired data on CDAI and CRP. The threshold for statistical significance was set at α = 
0.05. 
RESULTS 
From the total group of 279 Crohn's patients studied, 211 patients (76.0%) were responders (with 53.3% entering 
clinical remission), 59 (21.0%) were nonresponders, and nine (3.0%) patients could not be evaluated because of 
confounding factors (psychiatric disorders, n = 3; short bowel syndrome, n = 1; pouchitis, n = 1; stoma, n = 1; 
acute surgery, n = 2; liver transplant, n = 1). These nine patients were not included in further analysis. The 
response and nonresponse rates did not differ among fistulizing (75.0%, 25.0%) or refractory luminal subgroups 
(79.0%, 21.0%). 
Of 270 CD patients analyzed, 23 (9.0%) were pANCA positive and 129 (48.0%) had ASCA antibodies. 
Neither ASCA nor pANCA alone had any significant predictive value toward anti-TNF treatment response either 
in the total group nor in one of the subgroups (fistulizing or refractory luminal disease) (Table 2). 
Further the combination of both markers was studied, but again no significant relation between response to 
treatment and any marker combination was seen (Table 2). However, in the patient subgroup with refractory 
luminal CD a trend toward nonresponse for patients carrying the combination ASCA-/pANCA+ was seen (Fig. 
1), although this strictly lacked significance (χ2 = 7.2; p = 0.067; df = 3). Of the 10 patients with this 
combination, five were nonresponders and three patients had only partial response. Nine of these patients 
presented with pure left-sided colitis. In contrast, all four ASCA-/pANCA+ patients in the fistulizing group were 
responders. Three had a complete response. These three patients had involvement of the ileum as well as the 
colon. The one patient with partial response had pure left-sided colitis. 
Table 3 represents the calculated sensitivity, specificity, and predictive values for the serological markers and 
their combinations. Regarding the findings above, we were especially interested in the ASCA-/pANCA+ 
combination. In the subgroup of refractory disease the positive predictive value toward response is 50%, whereas 
in the fistulizing group it is 100%. 
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Finally, the correlation between the clinical response score, based on CDAI, and serum CRP levels was 
examined. For the total patient group, CRP levels at baseline were not different among the responders and 
nonresponders (p = 0.72), neither were the CDAI levels (p = 0.23). After anti-TNF treatment, a significant drop 
in CRP was observed only in the responder group. This was seen for the total group as well as for the refractory 
and fistulizing subgroups separately (Table 4). 
 
Table 2. Frequency of Serological Markers ASCA and pANCA (total n = 270) 
 Total (n = 270) Refractory CD (n = 183) Fistulizing CD (n = 87) 
Markers Response Nonresponse Response Nonresponse Response Nonresponse 
ASCA+ 101/129 (86.1%) 28/129 (13.9%) 67/81 (82.7%) 14/81 (17.3%) 34/48 (70.8%) 14/48 (29.2%) 
ASCA- 111/141 (78.0%) 31/141 (21.9%) 79/102 (77.5%) 23/102 (22.5%) 31/39 (79.5%) 8/39 (20.5%) 
pANCA+ 17/23 (73.9%) 6/23 (26.1%) 11/16 (68.7%) 5/16 (31.3%) 6/7 (85.7%) 1/7 (14.3%) 
pANCA- 194/247 (78.5%) 53/247 (21.5%) 135/167 (80.8%) 32/167 (19.2%) 59/80 (74.7%) 21/80 (25.3%) 
ASCA+/pANCA+ 8/9 (88.9%) 1/9 (11.1%) 6/6 (100.0%) 0/6 (0.0%) 2/3 (66.7%) 1/3 (33.3%) 
ASCA+/pANCA- 93/120 (77.5%) 27/120 (22.5%) 61/75 (81.3%) 14/75 (18.7%) 32/46 (69.6%) 14/46 (30.4%) 
ASCA-/pANCA+ 9/14 (64.3%) 5/14 (35.7%) 5/10 (50.0%) 5/10 (50.0%) 4/4 (100%) 0/4 (0.0%) 
ASCA-/pANCA- 101/127 (79.5%) 26/127 (20.5%) 74/92 (80.4%) 18/92 (19.6%) 27/35 (77.1%) 8/35 (22.9%) 
 
Table 3. Sensitivity, Specificity, PPV, and NPV for the Serological Markers and Their Combination in (a) the 
Total Group, (b) the Subgroups of Refractory CD, and (c) the Subgroup of Fistulizing Disease 
 Response Nonresponse 
 Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV 
Total group         
ASCA 0.48 0.53 0.78 0.22 0.47 0.52 0.22 0.78 
pANCA 0.08 0.90 0.74 0.21 0.10 0.92 0.26 0.79 
ASCA+/pANCA+ 0.04 0.98 0.89 0.22 0.02 0.04 0.11 0.78 
ASCA+/pANCA- 0.44 0.54 0.78 0.21 0.46 0.56 0.23 0.79 
ASCA-/pANCA+ 0.04 0.92 0.64 0.21 0.08 0.96 0.36 0.79 
ASCA-/pANCA- 0.48 0.56 0.80 0.23 0.44 0.52 0.20 0.77 
Refractory CD         
ASCA 0.46 0.62 0.83 0.23 0.38 0.54 0.17 0.77 
pANCA 0.08 0.86 0.69 0.19 0.14 0.92 0.31 0.81 
ASCA+/pANCA+ 0.04 1.00 1.00 0.21 0.00 0.96 0.00 0.79 
ASCA+/pANCA- 0.42 0.62 0.81 0.21 0.38 0.58 0.19 0.79 
ASCA-/pANCA+ 0.03 0.86 0.50 0.18 0.14 0.97 0.50 0.82 
ASCA-/pANCA- 0.51 0.51 0.80 0.21 0.49 0.49 0.20 0.79 
Fistulizing CD         
ASCA 0.52 0.36 0.71 0.21 0.64 0.48 0.29 0.79 
PANCA 0.09 0.95 0.86 0.26 0.45 0.91 0.14 0.74 
ASCA+/pANCA+ 0.03 0.96 0.67 0.26 0.04 0.97 0.33 0.74 
ASCA+/pANCA- 0.49 0.39 0.70 0.21 0.61 0.51 0.30 0.79 
ASCA-/pANCA+ 0.06 1.00 1.00 0.27 0.00 0.94 0.00 0.73 
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Figure 1. Percentage of responders/nonresponders in function of marker combinations ASCA/pANCA for 
patients with refractory CD (n = 183). 
 
 
Table 4. CDAI and CRP According to Response in the Refractory and Fistulizing Subgroups 
 Total Refractory Fistulizing 
 Response Nonresponse Response Nonresponse Response Nonresponse 
CDAI       
Mean baseline CDAI 258 312 272 321 218 282 
Mean CDAI difference -139 -32 -149 -16 -109 -73 
Significance p < 0.001 ns p < 0.001 ns p < 0.001 ns 
CRP (mg/L)       
Mean baseline CRP 28.94 26.34 29.80 28.57 26.36 20.20 
Mean CRP difference -19.28 -4.49 -20.14 -4.59 -16.67 -6.45 
Significance p < 0.001 ns p < 0.001 ns p < 0.001 ns 
 
DISCUSSION 
Monoclonal antibodies to anti-TNF are a breakthrough for the treatment of refractory Crohn's disease. The drug 
also has impressive potential of fistula healing. The fact that one third of patients show no response makes the 
search for predictive factors for response very important. Again this shows that the pathogenesis of IBD is 
complex and only little understood. Assessing risk factors or predictors of therapeutic outcome has great 
potential in medicine; patients likely to benefit from certain drugs can be selected in this way, with greater 
success rates and lower costs as direct consequences. 
In this study, the value of serological markers ASCA and pANCA in predicting response to anti-TNF treatment 
was assessed. Of all patients evaluable for response, 78.1% responded to the treatment (remission or partial 
response) and 21.9% had no response. These figures are in line with previous reports (1, 2). The prevalence of 
ASCA (48.0%) and pANCA (9.0%) are also consistent with other series in the literature (6, 7, 9). 
Neither ASCA nor pANCA, either alone or in combination, could predict response to anti-TNF treatment. For 
the marker combination ASCA-/pANCA+ higher nonresponse rates were observed in the subgroup of patients 
with refractory luminal disease, although this did not reach significance. Interestingly, in this respect is that also 
other investigators very recently associated distinct ANCA patterns with differences in response to infliximab, 
including pANCA positivity and poor response (25, 26). 
The fact that the ASCA-/pANCA+ subgroup lacked significance in our study might be due to the small number 
of patients presenting with this specific combination of markers (14/270; 5.2%). Because the specific marker 
combination ASCA-/pANCA+ is expected to be rare among CD patients, studying even larger cohorts of 
patients will be necessary to prove its true value in predicting response. Furthermore, and remarkably, the trend 
was seen only in the refractory subgroup and in patients with fistulizing disease, and this marker combination 
responded well to infliximab. This raises the question as to whether these two behavioral types of Crohn's 
disease could be different entities. 
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The evolution in CRP correlated well with the clinical response score, based on CDAI. For responders, a 
significant drop in CRP was seen, whereas this drop lacked for nonresponders. Because the CDAI is partially 
based on subjective data (as patients have to score their general well-being and rate their pain), response could 
therefore more objectively be scored using CRP. We observed significantly lower baseline CDAI levels in 
fistulizing CD compared with refractory CD (Table 4), probably a consequence of different symptoms and 
medication, parameters implicated in the CDAI. This difference in baseline levels was not observed for the CRP. 
Therefore, CRP levels could give a more standardized vision of the disease activity status. 
In conclusion, this study examined the role of serological markers in predicting therapy response to infliximab. 
Neither ASCA, pANCA, nor their combination could predict response. However, the question remains whether 
the marker combination pANCA+/ASCA- is predictive of nonresponse to infliximab in CD patients with severe 
refractory luminal disease. Finally, clinical response, which is now assessed based on CDAI differences, can be 
scored more objectively by means of CRP levels, as this parameter correlates well with therapy outcome. 
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